Eli Lilly Smashes Q1 Estimates with Surging Zepbound and Mounjaro Sales, Raises Full-Year Forecast

Eli Lilly & Co. reported first-quarter earnings that significantly exceeded Wall Street's predictions, fueled by robust sales of its weight loss medication Zepbound and diabetes treatment Mounjaro. The company subsequently increased its full-year revenue and profit outlook, reflecting confidence in continued growth.

Revenue for the quarter hit $19.80 billion, a 56% jump compared to last year, topping analysts' estimates of $17.62 billion. Adjusted earnings per share came in at $8.55, well above the anticipated $6.66. Shares reacted positively in premarket trading, leaping more than 7%.

Mounjaro's global sales surged 125% to $8.66 billion, with U.S. sales contributing $4.2 billion alone-outpacing expectations by a hefty margin. Meanwhile, Zepbound continues its climb, pulling in $4.16 billion in U.S. revenue, an 80% increase year-over-year despite pricing pressures in the market.

The company retains a dominant grip on the expanding GLP-1 drug sector aimed at obesity and diabetes, commanding 60.1% market share in the U.S. for the quarter. Competitor Novo Nordisk trails behind with 39.4%, highlighting Eli Lilly's leading position.

U.S. prescription volumes rose 49% during the quarter, driven primarily by demand for these two drugs. This growth partially offset lower realized prices, especially for Zepbound and Lilly's psoriatic arthritis medication.

CEO David Ricks reported that the recent launch of Foundayo-the company's GLP-1 pill for obesity-came after this quarter and thus is absent from the current results. Yet early figures reveal over 20,000 patients have started on Foundayo within weeks of its release, with daily new starts surpassing 1,000.

Interestingly, 80% of those initiating Foundayo had no previous experience with GLP-1 treatments, suggesting the drug is reaching new patient segments. Still, some analysts describe the launch pace as modest when compared to rival products that entered the market earlier.

Looking ahead, Eli Lilly expects continued volume gains offsetting pricing pressures tied to broader U.S. government drug deals and competitive cash pricing. Ricks anticipates worldwide GLP-1 patient numbers growing from roughly 20 million at the end of last year to about 30 million by year-end 2026.

All told, Eli Lilly's latest quarterly performance underlines its stronghold in a lucrative therapeutic area as it betters its financial guidance. The real question may be whether Foundayo can replicate the momentum of its injectable peers or merely add incremental volume in an increasingly crowded field.